class members

Elmiron Eye Damage (Maculopathy) Canadian Class Action

Documents

CONSUMER LAW GROUP is investigating a Canada-wide class action lawsuit against Janssen and IVAX Research, LLC for the side-effect of their drug Elmiron (pentosan polysulfate sodium), which can cause an eye disorder called maculopathy (a progressive disease that can lead to vision loss, usually in both eyes) in some patients.

The lawsuit is based on the allegation that the makers of Elmiron failed to properly warn the public about the risk of irreversible vision damage.

Elmiron is an oral prescription drug used to treat discomfort or bladder pain associated with interstitial cystitis, a chronic condition that causes bladder pain and pressure.

Over time, more and more studies have revealed the link between Elmiron and maculopathy:

• In November 2018, the medical journal Ophthalmology published an article entitled Pigmentary Maculopathy Associated With Chronic Exposure to Pentosan Polysulfate Sodium whereby it was found that chronic exposure to the drug caused unique pigmentary maculopathy - specifically, injury to the retinal pigment epithelium, a layer of cells that nourishes the retina.

• In April 2019, the Journal of Urology published an article entitled Chronic Exposure to Pentosan Polysulfate Sodium is Associated with Retinal Pigmentary Changes and Vision Loss whereby it was found that patients with a history of IC who did not take pentosan polysulfate sodium did not have the unique form of pigmented maculopathy present in patients who took the drug.

• In October 2019, the medical journal Ophthalmic Surgery, Lasers and Imaging Retina published an article entitled Progressive Maculopathy After Discontinuation of Pentosan Polysulfate Sodium whereby it was found that the toxicity was greater in patients who took more of the drug.

• In November 2019, the British Journal of Ophthalmology published an article entitled Association of macular disease with long-term use of pentosan polysulfate sodium: findings from a US cohort whereby it was found that pentosan users had significantly increased odds of macular disease at 7 years.

• In February 2020, the Canadian Urological Association Journal published an article entitled Possible Drug-Induced, Vision-Threatening Maculopathy Secondary to Chronic Pentosan Polysulfate Sodium (Elmiron®) Exposure whereby it was found that pentosan users had significantly increased odds of macular disease at 7 years.

If you or someone you know has taken Elmiron and suffered eye injury and you wish more information on potential compensation or to be kept advised of the status of the Elmiron Eye Damage (Maculopathy) Canadian Class Action or any resulting compensation thereof in Canada, Ontario or Quebec, please provide your contact information to our law firm using the form below.

IF YOU WISH TO JOIN THE CLASS ACTION OR TO SIMPLY GET MORE INFORMATION, PLEASE COMPLETE THE FORM BELOW. Please note that providing your information creates no financial obligation for you. You are not charged any fee or cost for joining this class action. Our law firm is paid a contingency fee from the compensation recovered, only if the class action is successful. All information contained in this transmission is confidential and Consumer Law Group agrees to protect this information against unauthorized use, publication or disclosure.

Join This Class Action

 
Class Action: Elmiron Eye Damage (Maculopathy) Canadian Class Action
First Name:
Last Name:
Email:
Confirm Email:
Address:
City:
Province:
Country:
Postal Code:
Home phone:
Work phone:
Cell phone:
Fax:
Damages or Symptoms experienced:
Other Comments:
Please add my email address to the CLG.org mailing list to receive timely emails containing information on this class action and information on other CLG.org class actions. Information on class actions includes new class action announcements, relevant class action information updates, and class action payout information.

Disclaimer: The Consumer Law Group website is not intended to create an attorney-client relationship between you and the firm. By submitting your information to us, you are not creating an attorney-client relationship with the firm, although the information will be kept confidential. An attorney-client relationship may be formed only after we check for conflicts of interest and the firm and you sign a mandate agreement. The firm may contact you about your legal claim to discuss representation options. Because of the volume of e-mails, we cannot promise to respond to every submission.

In any class action lawsuit, it is the court that approves who will be eligible for participation in the class. If you feel you may qualify for damages or remedies that might be awarded in this class action litigation, we request you fill out the above form to help us determine if you are a legitimate member of the class or to make sure you get any court mailings about the case. However, the return of the above form does not guarantee you any type of compensation.


Enter the number above




Post a Comment